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ABSTRACT  23 
Saliva may be a useful alternative matrix for monitoring levofloxacin concentrations in multi-24 
drug resistant TB patients. The objectives of this study were: a) to evaluate the correlation 25 
between plasma and salivary Lfx concentrations in MDR-TB patients; and b) to gauge the 26 
possibility of using saliva as an alternative sampling matrix for therapeutic drug monitoring 27 
of Lfx in TB endemic areas. This was a prospective pharmacokinetic study that enrolled MDR-28 
TB patients receiving levofloxacin (Lfx; 750-1000mg once daily dosing) under standardized 29 
treatment regimen in Nepal. Paired blood and saliva samples were collected at steady state. 30 
Lfx concentrations were quantified using liquid chromatography- tandem mass 31 
spectrometry. Pharmacokinetic parameters were calculated using non-compartmental 32 
kinetics. Lfx drug exposure was evaluated in 23 MDR-TB patients. During the first month, the 33 
median (IQR) area under the concentration-time curve (AUC0-24) was 67.09 (53.93-98.37) 34 
mg*h/L in saliva and 99.91 (76.80-129.70) mg*h/L in plasma, and the saliva plasma (S/P) 35 
ratio was 0.69 (0.53-0.99). Similarly, during the second month, the median (IQR) AUC0-24 was 36 
75.63 (61.45-125.5) mg*h/L in saliva and 102.7 (84.46-131.9) mg*h/L in plasma with a S/P 37 
ratio of 0.73 (0.66-1.18). Furthermore, large inter-and intra-individual variabilities in Lfx 38 
concentrations were observed. This study could not demonstrate a strong correlation 39 
between plasma and saliva Lfx levels. Despite a good Lfx penetration in saliva, the variability 40 
in individual saliva-to-plasma ratios limits the use of saliva as a valid substitute for plasma. 41 













INTRODUCTION  45 
Levofloxacin (Lfx) belongs to the group A fluoroquinolones (FQ) for treating multi-drug 46 
resistant tuberculosis (MDR-TB), defined as resistance to at least isoniazid and rifampicin (1). 47 
This class of drug is used throughout the course of treatment in the new, shorter nine-month 48 
regimen, in the longer 24-month MDR-TB regimen and additionally in the six-month regimen 49 
for rifampicin susceptible, isoniazid mono-resistant TB(2). Lfx and moxifloxacin have been 50 
used inter-changeably in the longer regimen, however, in developing countries Lfx is 51 
preferred due to affordability, availability, better safety profile and fewer drug interactions 52 
with other medications(3, 4). Acquired FQs resistance during standard treatment resulting in 53 
poor outcomes shown in a prospective observational cohort study is of serious concern(5). 54 
An earlier study by the same group showed that 11.2% (79/832) of MDR-TB patients 55 
developed FQ resistance without any baseline resistance, potentially due to sub-therapeutic 56 
systemic concentrations of drugs achieved(6, 7). Similarly, other pharmacokinetic studies on 57 
Lfx in MDR-TB patients found considerable pharmacokinetic variability among individuals, 58 
with at least 25% of the patients not attaining desired plasma concentration and area under 59 
the concentration vs time curve (AUC0-24)(3, 4, 8, 9). It is clear that Lfx concentrations do not 60 
always reach the desired concentrations while administered in a standard dose. Therefore, 61 
measuring Lfx concentrations in plasma or other alternative matrices (saliva and dried blood 62 
spots) could help clinicians make informed dosing decisions. More so now, as the TB 63 
treatment marches towards individualization, therapeutic drug monitoring (TDM) using 64 
saliva sampling might become a game changer in TB treatment due to specific advantages 65 
over plasma sampling, in low resource settings(10, 11). The efficacy of  Lfx is predicted by 66 
AUC0-24 and minimum inhibitory concentration (MIC)(12). Given as a monotherapy, the 67 











maximum bacterial kill (EC80) and 360 for the prevention of acquired drug resistance (12). 69 
Therefore, plasma AUC0-24  above 75 (if MIC is 0.5 mg/L) or 146 (if MIC is 1 mg/L) will be 70 
needed to attain the optimal target exposure for efficacy. With standard 750-1000 mg once 71 
daily dose, desired median peak concentration (Cmax) was 8-13 mg/L while, median time to 72 
reach Cmax  (tmax) was 1-2h and median half-life (t1/2) was 6-8h (13-15). Lfx demonstrated 73 
good penetration in extravascular body sites such as cerebrospinal fluid and cavitary lesions, 74 
due to rapid absorption and high volume of distribution(16, 17). Sasaki and Morishima 75 
compared Lfx levels in saliva and serum of eight healthy male volunteers after 76 
administration of 100 mg single dose. The study reported mean saliva/serum Lfx AUC ratio 77 
of 0.69 in fasting state and 0.56 in non-fasting state, indicating that saliva Lfx concentration 78 
could be useful for TDM(18). To date, however, studies comparing Lfx concentrations in 79 
plasma and saliva of MDR-TB patients have not been published. Saliva could be a useful 80 
alternative in predicting Lfx concentrations from plasma since sampling is non-invasive, fast, 81 
requires less rigid storage conditions, can be easily transported and is more suitable in 82 
children(19).  83 
Therefore, the aims of this study were as follows: a) to evaluate the correlation between 84 
plasma and salivary Lfx concentrations in MDR-TB patients; and b) to gauge the possibility of 85 
using saliva as an alternative sampling matrix for TDM of Lfx in TB endemic areas. 86 
PATIENTS AND METHODS  87 
Patients and design 88 
Study participants were MDR-TB patients undergoing treatment at German Nepal 89 











enrolled patients on treatment during 25/05/2016- 27/10/2017, with signed informed 91 
consent. The study protocol was approved by Ethical Review Board of Nepal Health Research 92 
Council, Kathmandu, Nepal (Reg. No 115/2016) and registered at clinicaltrials.gov (identifier 93 
number NCT 03000517). Patients (≥18 years) with newly diagnosed or previously treated 94 
MDR-TB (based on genotypic susceptibility testing to rifampicin by GeneXpert and culture) 95 
receiving Lfx as a part of their MDR-TB regimen were eligible for inclusion. Subjects were 96 
excluded if they had neurologic or severe extra-pulmonary manifestations of TB; had a body 97 
weight <35kg, were on medications for the treatment of renal disorders, were breast feeding 98 
or pregnant, were treated with aluminum- and magnesium containing antacids or ferrous 99 
sulphate, cimetidine, probenecid, theophylline, warfarin, zidovudine, digoxin or cyclosporine 100 
due to potential drug-drug interactions.  101 
The national tuberculosis guidelines for the programmatic management of MDR-TB in Nepal 102 
consists of an intensive phase of 8 months (with an addition of 4 months if there is no 103 
culture/ conversion at the end of 6 months) followed by a continuation phase of 12 months 104 
of treatment. Lfx (750-1000 mg once daily) was prescribed based on body weight as 105 
described in the guidelines for management of drug resistant tuberculosis in Nepal. Other 106 
drugs in this regimen included kanamycin (500-1000 mg/day i.m. injection), ethionamide 107 
(500-750mg/day), pyrazinamide (20-30 mg/kg/day) and cycloserine (500-750 mg/day).  108 
Study procedures 109 
To assess Lfx concentrations, steady state blood and saliva samples were collected before 110 
intake and at 1, 2, 4 and 8 hours after intake of Lfx. Patients were sampled twice i.e. at the 111 
end of the first month (15-30th day) and second month (45-60th day) of treatment. Plasma 112 











catalog no. 23-021-016) whereas, saliva samples were collected using two different 114 
techniques. Saliva samples were collected using a salivette® (Sarstedt, Nümbrecht, Germany, 115 
catalog no. 50-809-199) and additionally filtered using a membrane filter (0.2µm diameter, 116 
Merck KGaA, Darmstadt, Germany)(20). The collected plasma/saliva samples were 117 
centrifuged and frozen at -30°C until analysis. A standardized data collection (case report 118 
forms and excel database file) was created to record demographic and clinical data of the 119 
included patients. HIV test was carried out for all included patients as a part of treatment 120 
protocol, but none of the included patients were HIV positive. 121 
Drug quantification in plasma and saliva 122 
Lfx concentrations in human plasma and saliva were analyzed in the laboratory of the 123 
department of Clinical Pharmacy and Pharmacology at the University Medical Center 124 
Groningen, Netherlands using a validated liquid-chromatography tandem mass spectrometry 125 
technique (LC-MS/MS)(21). The calibration curve was linear over a range of 0.10-5 mg/L for 126 
Lfx. To encompass concentrations levels above 5 mg/L, dilution integrity was determined to 127 
accurately measure concentrations levels up to 40mg/L.  128 
The pH of salivary samples was measured using a pH indicator strips (Merck KGaA, 129 
Darmstadt, Germany), encompassing the pH range from 2.0-9.0, with 0.5 pH units increment 130 
distinguished by color change. Two independent observers (S.G., SHJ.VDE.) recorded the 131 
results, and in case of differences consensus was reached in the presence of a third observer 132 
(A.GM.).  133 











PK analysis. For PK parameters, non-compartmental analysis was performed using 135 
MW/Pharm (version 3.82; Mediware, Groningen, the Netherlands). The PK parameters 136 
included: maximal plasma concentration (Cmax), corresponding time of Cmax (tmax), area under 137 
plasma concentration vs. time curve (AUC0-24), apparent volume of distribution (Vd/F), 138 
apparent clearance (CL/F), half-life (t1/2) and elimination constant for plasma and saliva (ke). 139 
Statistical analysis was performed using SPSS Inc. (v 23.0, Chicago IL, USA). Results are 140 
presented as medians with interquartile range (IQR) for continuous variables and number 141 
percentage (%) for categorical variables. The normal distribution of data was ascertained by 142 
skewness-kurtosis, visual inspection of boxplots and Shapiro-Wilk test. The non-parametric 143 
Wilcoxon signed rank test was used to assess the differences between plasma and saliva PK 144 
parameters, when applicable. Inter- and intra- individual pharmacokinetic variabilities were 145 
evaluated from the CV% calculated as the quotient of standard deviation divided by the 146 
mean plasma concentration multiplied by 100. Passing-Bablok regression was used to assess 147 
the relationship between saliva and plasma Lfx concentrations (R Statistical Software). All P 148 
values were reported as significant if P <0.05.  149 
RESULTS 150 
Study subjects. Twenty-three MDR-TB patients were included in the study and demographic 151 
and baseline clinical characteristics are shown in Table 1. In our study, 70% (16/23) were 152 
male. The median age was 32 (IQR 28-47 years), body weight was 48 (IQR 41-55 kg) with a 153 
body-mass index (BMI) of 18 (IQR 16-19 kg/m2). Based on BMI, 65% (15/23) of the patients 154 
were underweight, as a result once daily 750-1000 mg Lfx dosing resulted in mg/kg doses of 155 
17.14 (15.38-19.23). All 23 (100%) patients completed the first PK sampling (15-30th day). 156 











One patient was transferred out, while two-patients were shifted to pre-XDR category, 158 
whereas the remaining patient participated only in saliva sampling.   159 
Lfx PK.  160 
The steady-state Lfx PK parameters are mentioned in Table 2. During the first month, the 161 
median area under the concentration-time curve (AUC0-24) was 67.09 (IQR 53.93-98.37) 162 
mg*h/L in saliva and 99.91 (IQR 76.80-129.70) mg*h/L in plasma, and the saliva plasma (S/P) 163 
ratio was 0.69 (IQR 0.53-0.99). Moreover, the median Cmax was 7.03 (IQR 5.61-9.02) mg/L in 164 
saliva and 10.35 (9.10-11.44) mg/L in plasma with the S/P ratio of 0.68 (IQR 0.53-0.97). A 165 
moderate positive correlation (rs=0.50; p=0.016) was demonstrated between the saliva and 166 
plasma AUC0-24. Similarly, during the second month, the median AUC0-24 and Cmax were 75.63 167 
(IQR 61.45-125.5) mg*h/L and 8.30 (IQR 6.56-12.03) mg/L in saliva and 102.7 (IQR 84.46-168 
131.9) mg*h/L and 10.96 (IQR 9.34-11.58) mg/L in plasma. The median AUC0-24 S/P ratio was 169 
0.734 (IQR 0.66-1.18). This time, saliva and plasma AUC0-24 showed a strong positive linear 170 
relationship (rs =0.754; p=0.0001) compared to the first month. Assuming a Lfx plasma 171 
protein binding of 24%, the median free plasma fAUC0-24  was 75.93 (58.37-98.57 IQR) 172 
mg*h/L in the first month and 78.05 (64.19-100.24 IQR) mg*h/L in the second month of 173 
treatment. The median S/P ratios were 0.96 (0.95-1.25 IQR) and 0.88 (0.92-0.99 IQR) 174 
respectively. The unbound Lfx fAUC0-24  in plasma reflected its salivary AUC0-24 closely, with 175 
S/P ratio almost close  to 1. Lfx concentration-time curves for both plasma and saliva are 176 
shown in Figure 1.  177 
Furthermore, a trend towards moderately positive correlation (rs=0.379; p=0.021) was 178 











estimated linear regression equation). When saliva Cmin was below 2 mg/L, proportion of 180 
patients had plasma AUC0-24 below desired 146 (12)  given MIC was at 1 mg/L.  181 
 Passing Bablok regression analysis was used to evaluate the agreement between plasma 182 
and saliva Lfx concentrations. Figure 2 shows fitted Passing-Bablok regression that revealed a 183 
linear relationship and was close to the line of identity (x=y) with an estimated slope 95% CI 184 
of 1 (-2.11 to 2.57) for first month and 1.81 (-0.51 to 3.92) for second month. Similarly, the 185 
intercept was -1.85 (-9.81 to 16.42) and -7.17 (-21.26 to 0.95) respectively. In both months, 186 
95% CI range included 1 for slope and 0 value for intercept, thereby satisfying the condition 187 
for line of identity.  188 
The inter-individual variability was assessed in 208 Lfx measurements in plasma and 195 189 
measurements in saliva at 0, 1, 2, 4, and 8 h samples. We found large inter-individual 190 
variability in Lfx concentrations. Furthermore, intra-individual variability was evaluated for 191 
the same patient based on the Lfx concentrations in plasma and saliva, between first and 192 
second months of treatment. The median intra-individual variability CVintra was 8.77 (IQR 193 
3.56-24.90 %) in plasma and 24.25 (IQR 12.20-34.65 %) in saliva for (19/23) patients. In our 194 
study, the intra-individual variability was lower than inter-individual variability. Table 3 195 
shows inter-and intra-individual coefficients of variation for Lfx. The salivary pH ranged from 196 
4.5-8.0 for different individuals with a mean value of 5.78 in the first month and 5.96 in the 197 
second month. Lfx saliva-plasma ratio as a function of salivary pH are plotted together 198 
(Figure 3). 199 
DISCUSSION  200 
The presence of Lfx in MDR-TB regimen has been associated with greater treatment success 201 











trials have shown inadequate Lfx concentrations in plasma of MDR-TB patients that has 203 
refrained the drug from achieving its maximum efficacy(4, 8, 9). The measurement of drug 204 
concentrations in plasma of MDR-TB patients and dose adjustments thereafter have 205 
contributed positively to MDR-TB treatment outcomes(23). Yet, only few TB treatment 206 
centers worldwide have adopted TDM.  Officially, the importance of TDM in the 207 
management of patient’s sub-groups of drug-susceptible tuberculosis was first introduced in 208 
the clinical practical guidelines by the American Thoracic Society, Centers for Disease Control 209 
and Prevention and, Infectious Diseases Society of America and was endorsed by the 210 
European Respiratory Society and the US National Tuberculosis Controllers association(24). 211 
Among many logistic and financial challenges that have hindered TDM implementation, one 212 
problem is that venous sampling does not always have enough leverage in low-resource TB 213 
endemic settings, mainly due to the invasive nature of sampling, need of skilled personnel 214 
for venipuncture, potential infectious hazard, cooling requirements for transportation and 215 
storage, and high costs (11).  In this scenario, use of alternative and stress-free sampling 216 
matrixes such as saliva could imprint TDM strategy in the national TB treatment guidelines. 217 
Therefore, in this first study on salivary penetration of Lfx in MDR-TB patients, we evaluated 218 
saliva’s potential as an alternative sampling matrix and to explore whether it can 219 
quantitatively reflect plasma concentrations for TDM guided dosing. Overall, the salivary and 220 
plasma concentration-time profiles agreed well for different patients characterized by higher 221 
Lfx concentrations in plasma than in saliva except in 21% (5/23) of patients who had higher 222 
salivary concentrations. The amount of Lfx present in saliva is representative of its free 223 
fraction in plasma that is able to passively diffuse to saliva, which happens almost 224 
instantaneously due to a concentration gradient(25). Given Lfx’s variable degree of protein 225 











concentrations22. The results obtained from plasma samples were more homogenous and 227 
consistent with recently published studies on MDR-TB patients by van’t Boveneind-228 
Vrubleuskaya et al. and Peloquin et al. with similar median observed AUC0-24 and Cmax 229 
values(4, 15). In theory, several factors could explain the high inter-individual variability in 230 
saliva, such as salivary pH in combination with drug pKa, salivary flow rate, and mechanism 231 
of drug transport (passive or active)(25, 26). The degree of ionization in different 232 
compartments is generally explained by pH of the compartments and the pKa of the drug.  233 
For example, lipid soluble non-ionized drugs which are not extensively bound to plasma 234 
proteins can easily transfer across the phospholipid bilayer of salivary cell membranes 235 
compared to ionized hydrophilic ones which tend to retain in plasma(26, 27). The pKa values 236 
for Lfx are 5.35 (strongest acidic) and 6.72 (strongest basic) and a saliva pH range was 4.5-8 237 
25. In patients with high salivary Lfx levels, it could be hypothesized that higher salivary 238 
concentrations could be the function of acidic salivary pH and basic drug pKa values that 239 
permitted swift transfer of Lfx from plasma to saliva and ionization thereafter. However, due 240 
to the unavailability of actual drug pKa data and unbound Lfx fraction in plasma for 241 
individual patients,  we couldn’t attribute salivary pH alone to explain the variabilities in 242 
salivary Lfx concentrations. In addition, patient hydration state is thought to influence 243 
parotid salivary flow rates and in turn saliva derived drug concentrations. As saliva mainly 244 
constitutes water (97-99.5%) originating from plasma by acinar cells, it is hypothesized that 245 
decrease in water volume due to dehydration would result in loss of salivary production (28). 246 
Fischer and Ship reported that dehydration significantly decreases the salivary output (29) 247 
but could not establish a strong correlation between biological markers of hydration 248 
(haematocrit, haemoglobin, serum sodium, plasma protein, creatinine, serum and urine 249 











hydration/dehydration status on salivary Lfx concentrations needs to be studied. 251 
Furthermore, presence of active transport channels might have contributed to high salivary 252 
concentrations, which have been studied for some peptides like insulin but not for Lfx yet 253 
and needs to be validated(27). 254 
A noteworthy finding of our study was that Lfx in saliva does not accurately predict its 255 
plasma levels, due to variable S/P ratios at different months of treatment and large inter-256 
individual variability in Lfx saliva concentrations CV% (min, max) of 44.90% and 94.29%. 257 
Furthermore during the second month of treatment, high inter-individual variabilities were 258 
observed at mean t4 concentrations in both matrixes (Figure 1), cause of which could not be 259 
identified since the clinical study procedures were uniform and patients were on the same 260 
regimen for at least first two months of treatment.  261 
This observation is not surprising as anti-TB drugs (levofloxacin, moxifloxacin, isoniazid, 262 
rifampicin and linezolid among others) exhibit high rates of PK variability even in plasma. 263 
Moreover, alternative matrices for TDM such as dried blood spots and saliva rarely have the 264 
level of precision that plasma based assessment possess. Despite the limitations, the 265 
potential utility of saliva in semi-quantitative testing remains strong. Patients with Lfx Cmin 266 
below 2 mg/L in saliva were at the risk of lower plasma AUC0-24 (Figure 4). These patients are 267 
likely to benefit from  semi-quantitative saliva based TDM in resource limited settings. 268 
However, this simple and non-invasive saliva based TDM may present few a challenges. First, 269 
the sampling procedure using  salivette introduces variability in recovery depending on the 270 
type of cotton rolls used (plain cotton swab, cotton swab impregnated with citric acid, and 271 
synthetic cotton swab). We found that around 30% of Lfx was sorbed to plain cotton rolls 272 











should be standardized and well-controlled.  The salivette technique further requires  274 
centrifugation for recovery of collected saliva. Alternatively, saliva samples could be 275 
collected by compressing the cotton roll in a syringe equipped with membrane filter (20).  276 
Second, it will not be feasible to analyze Lfx levels in saliva by advanced LC-MS/MS in 277 
resource limited settings. It has been prior suggested that patients at risk of low FQ exposure 278 
can be distinguished from those with normal/high exposure by a semi-quantitative point of 279 
care test such as spectrophotometer/thin-layer chromatography at a local level (31). The 280 
early pre-selection using semi-quantitative testing will act as a gate-keeper, only selecting 281 
patients at risk to offer TDM with expensive high-performance liquid chromatography 282 
technique at regional level, thereby optimally allocating resources from already depleted TB 283 
programs (10, 31). Therefore, development of a simplified, affordable, point-of care tool for 284 
determination of Lfx levels in saliva should be a priority. Third, thermal instability of anti-TB 285 
drugs and the need of refrigeration and cooling conditions for transportation might be an 286 
issue. We recently investigated the impact of high temperature exposure on stability of Lfx 287 
and found that it was stable at 50°C for 10 days. This is advantageous, as it precludes the 288 
cooling requirements for transportation of samples to the laboratories for TDM. Preferably, 289 
in remote settings, dried blood spots sampling could be a feasible option due to longer 290 
stability at room temperature and transportation option by regular mail but still requires the 291 
advanced LC/MS-MS for analysis. Another attraction in the field of alternative sampling 292 
could be dried saliva spots but requires sensitive high cost equipment, analytical method 293 
development and validation, and  long term stability testing at higher temperatures.    294 
In this study, we could not use the Bland Altman method for graphical representation of 295 
mean and 95% (SD) limits of agreement between Lfx concentrations in plasma and saliva. 296 











concentrations were significantly different (p < 0.05) from 0, which violates one of the 298 
assumptions of Bland-Altman analysis. 299 
There were some limitations in our study. First, the sample size of 23 was rather small to 300 
explain the observed high Lfx inter- and intra- patient variability in saliva compared to 301 
plasma. To explain this effect in saliva, studies with sample size that ensures statistical 302 
power of more than 80% will be needed. Second, different predictors of salivary Lfx 303 
concentrations such as salivary flow rate were not studied. Despite the limitations, salivary 304 
Lfx concentrations could contribute as a valuable semi-quantitative pre-selection tool to 305 
identify patients’ sub-groups eligible for TDM using dried-blood spot. Patients with Lfx Cmin 306 
below 2 mg/L in saliva could benefit from TDM due to the risk of lower plasma AUC0-24.  307 
In conclusion, this study could not demonstrate any significant relationship between plasma 308 
and saliva Lfx levels. Although Lfx penetrated in saliva, the variability in individual saliva-to-309 
plasma ratios limits the use of saliva as a valid substitute for plasma. Despite the limitations, 310 
our data suggest that the potential utility of saliva in semi-quantitative testing remains 311 
strong. Patients with Lfx Cmin below 2 mg/L in saliva are likely to benefit from  semi-312 
quantitative saliva based TDM in resource limited settings.  313 
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Table 1: Baseline characteristics of all included patients 429 
Patient Characteristics Value 
Demographic (n=23)  
Male 16 (69.56) 
Age, years 32 (28-47) 
Body weight, kg 48 (41-55) 
Length, cm 165 (162-175) 
BMI (kg/m2) 17.96 (16.23-18.83) 
Underweight (<18.5 kg/m2) 15 (65.22) 
Normal (18.5-25.0 kg/m2) 8 (34.78) 
Co-morbidities  
Diabetes mellitus 2 (8.69) 
HIV  0 
Dose (mg/kg)  
Lfx 17.14 (15.38-19.23) 
Renal function, baseline  
Creatinine, µmol/L 70.72 (61.88-79.56) 
Urea, mg/dl 19 (15-23) 
Sodium, mmol/L 140 (134-144) 
Potassium, mmol/L 4.12 (3.83- 4.4) 















Table 2: Steady-state pharmacokinetic parameters for Lfx  435 
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- - 0.94 0.96 



















Data are presented as median (interquartile range). AUC0-24, area under the concentration-time 436 
curve; fAUC0-24, free Lfx AUC0-24 assuming plasma protein binding of 24%; Cmax, maximum 437 
concentration of drug; tmax, time at which Cmax occurred; CL/F, apparent total body clearance; Vd/F, 438 
apparent volume of distribution; t1/2e, elimination half-life; k, elimination rate constant.  439 
Table 3: Inter-individual (CVinter) and intra-individual (CVintra) variabilities of Lfx  440 
Inter-individual variability (n=23) Plasma concentration, mean (SD); 
(CVinter%) 
Saliva concentration, mean 
(SD);(CVinter%) 
Time (h) I month  II month I month II month  




















Intra-Individual variability, CVintra 
%  
8.77 (3.65-24.90) * 
(n=19) 
24.25 (12.20-34.65) * 
(n=20) 
*= Median (interquartile range). SD, standard deviation; CV%, co-efficient of variation.  441 
Legends for Figures. 442 












Figure 2: Passing-Bablok regression analysis of mean Lfx concentrations (t0, 1, 2, 4, 8 h) in 445 
plasma and saliva for two months. The bold solid line represents the Passing-Bablok fitted 446 
line, whereas the solid line is the line of identity. The dashed lines are 95% CI; r is the 447 
spearman’s rank co-relation; and N is the number of paired mean plasma and saliva 448 
concentrations.  449 
 450 
Figure 3: Lfx saliva-plasma ratios at different time-points (0, 1, 2, 4, 8h) and salivary pH at 451 
first and second month of treatment.  452 
 453 
Figure 4: Lfx Cmin in saliva to predict plasma AUC0-24. The vertical line at 2 mg/L is the Cmin cut-454 
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